Erratum to: Efficacy of Liraglutide in a Real-Life Cohort, (Diabetes Ther, 10.1007/s13300-014-0062-2;Efficacy of Liraglutide in a Real-Life Cohort

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 193-206

  Heymann, Anthony ^a   Maor, Yasmin ^b   Goldstein, Inbal ^c   Todorova, Lora ^d   Schertz Sternberg, Perlit ^e   Karasik, Avraham ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c Maccabi Health Organization   (Israel)

^d Novo Nordisk FemCare AG   (Switzerland)

^e NOVO NORDISK A S   (Denmark)

Author keywords

Clinical effectiveness; Diabetes; Endocrinology; Incretin; Liraglutide; Obesity; Routine clinical practice; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; FEMALE; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

EID: 84922005537     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0069-8     Document Type: Erratum

References (24)

1. Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem. 2004;47:4128–34.
2. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, 1860 LIRA-DPP-4 Study Group, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447–56.
3. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448–60.
4. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
5. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–36.
6. Unger J. Liraglutide: can it make a difference in the treatment of type 2 diabetes? Int J Clin Pract. 2010;64(Suppl 167):1–3.
7. Marre M, Shaw J, Brandle M, Wan Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.
8. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care. 2009;32:84–90.
9. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81.
10. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met + TZD). Diabetes Care. 2009;32:1224–30.
11. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.
12. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
13. Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther. 2013;4:27–40.
14. Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, et al. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol. 2013;50:943–9.
15. Heymann A, Chodick G, Halkin H, Karasik A, Shalev V, Shemer J, et al. The implementation of managed care for diabetes using medical informatics in a large Preferred Provider Organization. Diabetes Res Clin Pract. 2006;71:290–8.
16. Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann A. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol. 2011;152:345–9.
17. World Health Organization. The international classification of diseases, 9th revision, clinical modification (ICD-9-CM), sixth edition. http://www.who.int/classifications/icd/en/. Accessed 10 March 2014.
18. NICE Technology Appraisal Guidance 203. Liraglutide for the treatment of type 2 diabetes mellitus. Oct 2010. http://www.nice.org.uk/guidance/TA203. Accessed 27 October 2013.
19. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract. 2012;97:27–42.
20. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013;15:42–54.
21. Garber AJ, Matthews D, Zinman B, Thompson AB, Falahati A, Guerci B. The effect of disease stage, indicated by number of previous oral antidiabetic agents, on the response to liraglutide in type 2 diabetes. Diabetes. 2011;60 (Suppl 1):A265 (Abstract 967P).
22. Ratner R, Brett J, Khurtoryansky N, Aroda VR. Identifying predictors of response to liraglutide in type 2 diabetes using recursive partitioning analysis. Diabetologia. 2012;55(Suppl 1):S332 (Abstract 806-P).
23. Ross SA, Ballantine J. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes. Curr Med Res Opin. 2013;29:1617–26.
24. European Medicines Agency. Directive 2001/20/EC. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF. Accessed 27 October 2013.